China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Nov, 2013   |   65  Pages   |   ResearchInChina   |   Format : PDF

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, Chinas injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

Status quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
Status quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
Operation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.

1 Overview of LVP
1.1 Definition and Classification
1.2 Industry Chain

2 Overview of China LVP Industry Development
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 Development Forecast

3 Chinese LVP Market Segments
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysis Solution

4 Main Companies
4.1 Kelun Pharma
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Clients and Suppliers
4.1.6 R & D and Investment
4.1.7 LVP Business
4.1.8 Development Forecast
4.2 China Resources Double-Crane
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Major Clients
4.2.6 LVP Business
4.2.7 Development Forecast
4.3 Fengyuan Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 LVP Business
4.3.7 Development Forecast
4.4 Huaren Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.4.7 Development Forecast
4.5 Southwest Pharmaceutical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Clients
4.5.6 LVP Business
4.5.7 Development Forecast
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation
4.6.3 Shijiazhuang No.4 Pharmaceutical
4.7 Other Companies
4.7.1 Qingzhou Yaowang Medicine
4.7.2 Jilin Dubang Pharmaceutical
4.7.3 Shandong Lukang Cisen Pharmaceutical
4.7.4 China Otsuka Pharmaceutical

5 China LVP Industry Summary and Development Prediction
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with obvious Competitive Edges
5.3 Product Structure to Upgrade and New LVP products Development to be Trend

Medical Devices Markets in China
China's demand for Medical Devices has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consum
China Medical Devices Report
The China Medical Devices Report features forecasts for medical devices production, imports, exports and healthcare expenditure by Espicom, a Business Monitor International company (BMI). These forecasts focus on Consumables, Diagnostic Imaging Apparatus, Dental Products, Orthopaedic and Prost
The 2013-2018 Outlook for Medical Devices Outsourcing in Greater China
This econometric study covers the latent demand outlook for medical devices outsourcing across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administr
The 2013-2018 Outlook for Medical Devices and Diagnostics in Greater China
This econometric study covers the latent demand outlook for medical devices and diagnostics across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special admin
Cardiac Medical Devices - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015

BRICSS Market Watch: The broad health care division has been witnessing a rapid growth and technological improvements varying from sector to sector since the past 3-5 years. The evolution of cardiac devices has opened new vistas in the health care industry. Growth rat

Select a Licence type

Custom Research

We are known to provide exact requirements. Try our CUSTOM RESEARCH option and get the exact search result you are searching for.

Contact Us

Postal Address:
808, Real Tech Park, 8th Floor, Sector - 30A, Vashi, Navi Mumbai - 400703 , INDIA .
Telephone: +91 22 27810772, 27810773
Email: info@marketreportsonchina.com
Fax Number: +91 22 27812707

Follow Us On: